Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
37 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

RXRX — Recursion Pharmaceuticals, Inc. Dilution Risk Tracker

Track RXRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track RXRX — Get alerts when the score changes →

As of August 28, 2026, Recursion Pharmaceuticals, Inc. (RXRX) has a DilutionWatch DilutionScore of 37/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Recursion Pharmaceuticals, Inc. has a market capitalization of $1.77B, 535.34M shares outstanding, 10 institutional holders tracked. Stored dilution-related fields include ATM program capacity of $300.00M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
40
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 9%
💰 Capital Raise model 18%
• Active ATM program with $300M remaining capacity
🔔 Track RXRX — Get forecast alerts →

Market Data

Market Cap$1.77B
Shares Outstanding535.34M
FloatN/A
Cash$545.68M
Debt$723.0K
Short InterestN/A

Institutional Holdings

10 institutional holders · 226.35M shares
#1 Vanguard Group Inc 47.19M shares
#2 Blackrock Inc. 38.87M shares
#3 ARK Investment Management, LLC 37.32M shares
+ 7 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest180.77M
Days to Cover9.3
% of FloatN/A
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2022-12-31
4 INSIDER TRANSACTION 2026-07-02
4 INSIDER TRANSACTION 2026-06-22
4 INSIDER TRANSACTION 2026-06-22
4 INSIDER TRANSACTION 2026-06-22
Full SEC filing analysis available with free account

Recent News

Factual RXRX Dilution Snapshot

Recursion Pharmaceuticals, Inc. (RXRX) has a DilutionScore of 37/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track RXRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking RXRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for RXRX
RXRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.